RMC-7977 caused tumour growth inhibition and induced multiple tumour regressions across a larger panel of 15 PDAC, CRC and NSCLC CDX and patient-derived xenograft (PDX) models bearing KRASG12X mutations and co-mutations representative of the genomic landscape of patients with KRAS-mutant cancers (Fig. 3e). This evidence concerns the gene KRAS and neoplasm.